Evercore ISI analyst Glenn Schorr maintained a Buy rating on KKR & Co (KKR – Research Report) yesterday and set a price target of $165.00.

Cotiviti nears $3 billion deal to acquire Edifecs, rejecting higher bid from UnitedHealth. Antitrust concerns cited.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

KKR & Co's fourth-quarter assets under management fell short of expectations on Tuesday, dampening the optimism around ...

The firm said it would increase its investment in the companies by $1.1 billion in total as part of its unusual strategy of ...

U.S. private equity firm KKR has sweetened its offer for Japan's Fuji Soft by 4%, the latest salvo in its protracted and ...

CENTRAL TRUST Co increased its position in KKR & Co. Inc. (NYSE:KKR – Free Report) by 27.0% in the 4th quarter, according to ...

KKR & Co.’s business of arranging financing for its portfolio companies and other firms reported record annual fees last year ...

Last week, larger rival Blackstone also beat quarterly profit expectations, driven by a pickup in dealmaking. KKR's assets ...

KKR-backed healthcare data company Cotiviti is close to securing a deal to buy smaller rival Edifecs for just over $3bn, after it opted against accepting a higher bid from UnitedHealth Group out of ...

Private equity giant KKR (KKR) has upped its offer price for Japan-based IT company Fuji Soft in its ongoing complex takeover ...

KKR posted fourth-quarter net income growth as lower expenses offset a drop in revenue, and assets under management at the buyout firm grew as it prepared for a potential deal bonanza in the second ...